Back to Search
Start Over
Miller Fisher syndrome following COVID-19 vaccines: A scoping review.
- Source :
-
Acta neurologica Scandinavica [Acta Neurol Scand] 2022 Nov; Vol. 146 (5), pp. 604-609. Date of Electronic Publication: 2022 Aug 08. - Publication Year :
- 2022
-
Abstract
- Background and Purpose: Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID-19 vaccination. We aimed to identify and characterize MFS following COVID-19 vaccination.<br />Materials and Methods: Relevant studies reported on during the COVID-19 pandemic were identified in the MEDLINE, Embase, and other databases.<br />Results: Nine cases of MFS following COVID-19 vaccination from various regions were included. Unlike MFS following COVID-19 infection, patients with MFS following COVID-19 vaccination frequently presented with anti-GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID-19 vaccination, only two of nine (22%) cases of MFS following COVID-19 vaccination had developed after viral-vector-related vaccine administration.<br />Conclusions: Miller Fisher syndrome following COVID-19 vaccination seems to have a different pathophysiology from MFS following COVID-19 infection and GBS following COVID-19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID-19 vaccination.<br /> (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Details
- Language :
- English
- ISSN :
- 1600-0404
- Volume :
- 146
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Acta neurologica Scandinavica
- Publication Type :
- Academic Journal
- Accession number :
- 35938305
- Full Text :
- https://doi.org/10.1111/ane.13687